{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:22:31Z","timestamp":1794864151861,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01040-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:27:51Z","timestamp":1751372871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Enrichment of gut-derived metabolites in a Parkinson\u2019s disease subtype with REM sleep behavior disorder"],"prefix":"10.1038","volume":"11","author":[{"given":"Sunjae","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8023-6011","authenticated-orcid":false,"given":"Jae Woo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7673-034X","authenticated-orcid":false,"given":"Ara","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9663","authenticated-orcid":false,"given":"Han-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1040_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson\u2019s disease. Lancet 403, 293\u2013304 (2024).","journal-title":"Lancet"},{"key":"1040_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","volume":"17","author":"D Berg","year":"2021","unstructured":"Berg, D. et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat. Rev. Neurol. 17, 349\u2013361 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1040_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"1040_CR4","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"1040_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.nbd.2011.10.014","volume":"46","author":"MG Cersosimo","year":"2012","unstructured":"Cersosimo, M. G. & Benarroch, E. E. Pathological correlates of gastrointestinal dysfunction in Parkinson\u2019s disease. Neurobiol. Dis. 46, 559\u2013564 (2012).","journal-title":"Neurobiol. Dis."},{"key":"1040_CR6","doi-asserted-by":"publisher","unstructured":"Romano, S. et al. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. Npj Parkinsons Dis. 7, https:\/\/doi.org\/10.1038\/s41531-021-00156-z (2021).","DOI":"10.1038\/s41531-021-00156-z"},{"key":"1040_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34667-x","volume":"13","author":"ZD Wallen","year":"2022","unstructured":"Wallen, Z. D. et al. Metagenomics of Parkinson\u2019s disease implicates the gut microbiome in multiple disease mechanisms. Nat. Commun. 13, 6958 (2022).","journal-title":"Nat. Commun."},{"key":"1040_CR8","doi-asserted-by":"publisher","unstructured":"Huang, B. et al. Gut microbiome dysbiosis across early Parkinson\u2019s disease, REM sleep behavior disorder and their first-degree relatives. Nat. Commun. 14, https:\/\/doi.org\/10.1038\/s41467-023-38248-4 (2023).","DOI":"10.1038\/s41467-023-38248-4"},{"key":"1040_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrn3346","volume":"13","author":"JF Cryan","year":"2012","unstructured":"Cryan, J. F. & Dinan, T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701\u2013712 (2012).","journal-title":"Nat. Rev. Neurosci."},{"key":"1040_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.molcel.2020.03.005","volume":"78","author":"A Koh","year":"2020","unstructured":"Koh, A. & Backhed, F. From association to causality: the role of the gut microbiota and its functional products on host metabolism. Mol. Cell 78, 584\u2013596 (2020).","journal-title":"Mol. Cell"},{"key":"1040_CR11","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 167, 1469 (2016).","journal-title":"Cell"},{"key":"1040_CR12","doi-asserted-by":"publisher","unstructured":"Roede, J. R. et al. Serum metabolomics of slow vs. rapid motor progression Parkinson\u2019s disease: a pilot study. PLoS ONE 8, https:\/\/doi.org\/10.1371\/journal.pone.0077629 (2013).","DOI":"10.1371\/journal.pone.0077629"},{"key":"1040_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/bs.acc.2020.09.003","volume":"104","author":"J Troisi","year":"2021","unstructured":"Troisi, J. et al. Metabolomics in Parkinson\u2019s disease. Adv. Clin. Chem.104, 107\u2013149 (2021).","journal-title":"Adv. Clin. Chem."},{"key":"1040_CR14","doi-asserted-by":"publisher","unstructured":"Shao, Y. P. et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, https:\/\/doi.org\/10.1186\/s13024-021-00425-8 (2021).","DOI":"10.1186\/s13024-021-00425-8"},{"key":"1040_CR15","doi-asserted-by":"publisher","unstructured":"Shao, Y. P. & Le, W. D. Recent advances and perspectives of metabolomics-based investigations in Parkinson\u2019s disease. Mol. Neurodegener. 14, https:\/\/doi.org\/10.1186\/s13024-018-0304-2 (2019).","DOI":"10.1186\/s13024-018-0304-2"},{"key":"1040_CR16","doi-asserted-by":"publisher","unstructured":"Paul, K. C. et al. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson\u2019s disease. Mol. Neurodegener. 18, https:\/\/doi.org\/10.1186\/s13024-023-00694-5 (2023).","DOI":"10.1186\/s13024-023-00694-5"},{"key":"1040_CR17","doi-asserted-by":"publisher","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","volume":"50","author":"DS Wishart","year":"2022","unstructured":"Wishart, D. S. et al. HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Res. 50, D622\u2013D631 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1040_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/bioinformatics\/btaa918","volume":"37","author":"B Shaker","year":"2021","unstructured":"Shaker, B. et al. LightBBB: computational prediction model of blood-brain-barrier penetration based on LightGBM. Bioinformatics 37, 1135\u20131139 (2021).","journal-title":"Bioinformatics"},{"key":"1040_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cca.2019.10.038","volume":"501","author":"B Sankowski","year":"2020","unstructured":"Sankowski, B. et al. Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson\u2019s disease. Clin. Chim. Acta 501, 165\u2013173 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"1040_CR20","doi-asserted-by":"publisher","first-page":"105557","DOI":"10.1016\/j.nbd.2021.105557","volume":"161","author":"P Borghammer","year":"2021","unstructured":"Borghammer, P. et al. Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiol. Dis. 161, 105557 (2021).","journal-title":"Neurobiol. Dis."},{"key":"1040_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13024-023-00694-5","volume":"18","author":"KC Paul","year":"2023","unstructured":"Paul, K. C. et al. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson\u2019s disease. Mol. Neurodegener. 18, 100 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1040_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamaneurol.2014.65","volume":"71","author":"DP Breen","year":"2014","unstructured":"Breen, D. P. et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 71, 589\u2013595 (2014).","journal-title":"JAMA Neurol."},{"key":"1040_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3233\/JPD-223179","volume":"12","author":"SJ Chen","year":"2022","unstructured":"Chen, S. J. et al. Alteration of gut microbial metabolites in the systemic circulation of patients with parkinson\u2019s disease. J. Parkinson's Dis. 12, 1219\u20131230 (2022).","journal-title":"J. Parkinson's Dis."},{"key":"1040_CR24","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1212\/WNL.0000000000004888","volume":"90","author":"M Fujimaki","year":"2018","unstructured":"Fujimaki, M. et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 90, e404\u2013e411 (2018).","journal-title":"Neurology"},{"key":"1040_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cca.2018.02.022","volume":"480","author":"G Nagesh Babu","year":"2018","unstructured":"Nagesh Babu, G. et al. Serum metabolomics study in a group of Parkinson\u2019s disease patients from northern India. Clin. Chim. Acta 480, 214\u2013219 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"1040_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4 (2021).","journal-title":"Mol. Neurodegener."},{"key":"1040_CR27","doi-asserted-by":"publisher","first-page":"e00556","DOI":"10.1002\/brb3.556","volume":"6","author":"L Haglin","year":"2016","unstructured":"Haglin, L. & Backman, L. Covariation between plasma phosphate and daytime cortisol in early Parkinson\u2019s disease. Brain Behav. 6, e00556 (2016).","journal-title":"Brain Behav."},{"key":"1040_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/mds.28016","volume":"35","author":"C Shin","year":"2020","unstructured":"Shin, C., Lim, Y., Lim, H. & Ahn, T. B. plasma short-chain fatty acids in patients with Parkinson\u2019s disease. Mov. Disord. 35, 1021\u20131027 (2020).","journal-title":"Mov. Disord."},{"key":"1040_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1006\/dbio.2000.9930","volume":"228","author":"N Fukushima","year":"2000","unstructured":"Fukushima, N., Weiner, J. A. & Chun, J. Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev. Biol. 228, 6\u201318 (2000).","journal-title":"Dev. Biol."},{"key":"1040_CR30","doi-asserted-by":"publisher","first-page":"18865","DOI":"10.3390\/ijms160818865","volume":"16","author":"K Farmer","year":"2015","unstructured":"Farmer, K., Smith, C. A., Hayley, S. & Smith, J. Major Alterations of phosphatidylcholine and lysophosphotidylcholine lipids in the substantia nigra using an early stage model of Parkinson\u2019s disease. Int. J. Mol. Sci. 16, 18865\u201318877 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"1040_CR31","doi-asserted-by":"publisher","first-page":"e209201","DOI":"10.1212\/WNL.0000000000209201","volume":"102","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Association of coffee consumption and prediagnostic caffeine metabolites with incident parkinson disease in a population-based cohort. Neurology 102, e209201 (2024).","journal-title":"Neurology"},{"key":"1040_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.0000000000003663","volume":"88","author":"PA LeWitt","year":"2017","unstructured":"LeWitt, P. A. et al. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology 88, 862\u2013869 (2017).","journal-title":"Neurology"},{"key":"1040_CR33","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/mds.21502","volume":"22","author":"T Annanmaki","year":"2007","unstructured":"Annanmaki, T., Muuronen, A. & Murros, K. Low plasma uric acid level in Parkinson\u2019s disease. Mov. Disord. 22, 1133\u20131137 (2007).","journal-title":"Mov. Disord."},{"key":"1040_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clineuro.2009.06.012","volume":"111","author":"E Andreadou","year":"2009","unstructured":"Andreadou, E. et al. Serum uric acid levels in patients with Parkinson\u2019s disease: their relationship to treatment and disease duration. Clin. Neurol. Neurosurg. 111, 724\u2013728 (2009).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1040_CR35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/oxfordjournals.aje.a008954","volume":"144","author":"JW Davis","year":"1996","unstructured":"Davis, J. W. et al. Observations on serum uric acid levels and the risk of idiopathic Parkinson\u2019s disease. Am. J. Epidemiol. 144, 480\u2013484 (1996).","journal-title":"Am. J. Epidemiol."},{"key":"1040_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/aje\/kwm127","volume":"166","author":"MG Weisskopf","year":"2007","unstructured":"Weisskopf, M. G., O\u2019Reilly, E., Chen, H., Schwarzschild, M. A. & Ascherio, A. Plasma urate and risk of Parkinson\u2019s disease. Am. J. Epidemiol. 166, 561\u2013567 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"1040_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","volume":"87","author":"T Hatano","year":"2016","unstructured":"Hatano, T., Saiki, S., Okuzumi, A., Mohney, R. P. & Hattori, N. Identification of novel biomarkers for Parkinson\u2019s disease by metabolomic technologies. J. Neurol. Neurosurg. Psychiatry 87, 295\u2013301 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1040_CR38","doi-asserted-by":"publisher","first-page":"E404","DOI":"10.1212\/WNL.0000000000004888","volume":"90","author":"M Fujimaki","year":"2018","unstructured":"Fujimaki, M. et al. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 90, E404 (2018).","journal-title":"Neurology"},{"key":"1040_CR39","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/mds.28068","volume":"35","author":"H Takeshige-Amano","year":"2020","unstructured":"Takeshige-Amano, H. et al. Shared metabolic profile of caffeine in parkinsonian disorders. Mov. Disord. 35, 1438\u20131447 (2020).","journal-title":"Mov. Disord."},{"key":"1040_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/nutrit\/nuaa103","volume":"79","author":"Y Dai","year":"2021","unstructured":"Dai, Y. & Liu, J. Omega-3 long-chain polyunsaturated fatty acid and sleep: a systematic review and meta-analysis of randomized controlled trials and longitudinal studies. Nutr. Rev. 79, 847\u2013868 (2021).","journal-title":"Nutr. Rev."},{"key":"1040_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plefa.2006.09.001","volume":"76","author":"G Irmisch","year":"2007","unstructured":"Irmisch, G., Schlafke, D., Gierow, W., Herpertz, S. & Richter, J. Fatty acids and sleep in depressed inpatients. Prostaglandins Leukot. Ess. Fat. Acids 76, 1\u20137 (2007).","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"key":"1040_CR42","doi-asserted-by":"publisher","unstructured":"Avallone, R., Vitale, G. & Bertolotti, M. Omega-3 fatty acids and neurodegenerative diseases: new evidence in clinical trials. Int. J. Mol. Sci. 20, https:\/\/doi.org\/10.3390\/ijms20174256 (2019).","DOI":"10.3390\/ijms20174256"},{"key":"1040_CR43","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41587-019-0233-9","volume":"37","author":"T Wilmanski","year":"2019","unstructured":"Wilmanski, T. et al. Blood metabolome predicts gut microbiome \u03b1-diversity in humans. Nat. Biotechnol. 37, 1217 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1040_CR44","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s11064-018-02705-0","volume":"44","author":"T Prorok","year":"2019","unstructured":"Prorok, T., Jana, M., Patel, D. & Pahan, K. Cinnamic acid protects the nigrostriatum in a mouse model of Parkinson\u2019s disease via peroxisome proliferator-activated receptoralpha. Neurochem. Res. 44, 751\u2013762 (2019).","journal-title":"Neurochem. Res."},{"key":"1040_CR45","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.cell.2013.11.024","volume":"155","author":"EY Hsiao","year":"2013","unstructured":"Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451\u20131463 (2013).","journal-title":"Cell"},{"key":"1040_CR46","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41586-022-04396-8","volume":"602","author":"BD Needham","year":"2022","unstructured":"Needham, B. D. et al. A gut-derived metabolite alters brain activity and anxiety behaviour in mice. Nature 602, 647 (2022).","journal-title":"Nature"},{"key":"1040_CR47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.biopsych.2020.09.025","volume":"89","author":"BD Needham","year":"2021","unstructured":"Needham, B. D. et al. Plasma and fecal metabolite profiles in autism spectrum disorder. Biol. Psychiatry 89, 451\u2013462 (2021).","journal-title":"Biol. Psychiatry"},{"key":"1040_CR48","doi-asserted-by":"publisher","unstructured":"Sun, C. Y. et al. p-cresol sulfate caused behavior disorders and neurodegeneration in mice with unilateral nephrectomy involving oxidative stress and neuroinflammation. Int. J. Mol. Sci. 21, https:\/\/doi.org\/10.3390\/ijms21186687 (2020).","DOI":"10.3390\/ijms21186687"},{"key":"1040_CR49","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/mds.27362","volume":"33","author":"RB Postuma","year":"2018","unstructured":"Postuma, R. B. et al. Validation of the MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 33, 1601\u20131608 (2018).","journal-title":"Mov. Disord."},{"key":"1040_CR50","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/mds.25037","volume":"27","author":"RB Postuma","year":"2012","unstructured":"Postuma, R. B. et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov. Disord. 27, 913\u2013916 (2012).","journal-title":"Mov. Disord."},{"key":"1040_CR51","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/bioinformatics\/bts515","volume":"28","author":"J Feng","year":"2012","unstructured":"Feng, J. et al. GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data. Bioinformatics 28, 2782\u20132788 (2012).","journal-title":"Bioinformatics"},{"key":"1040_CR52","first-page":"100388","volume":"4","author":"S Xu","year":"2023","unstructured":"Xu, S. et al. MicrobiotaProcess: a comprehensive R package for deep mining microbiome. Innovation 4, 100388 (2023).","journal-title":"Innovation"},{"key":"1040_CR53","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41587-023-01688-w","volume":"41","author":"A Blanco-M\u00edguez","year":"2023","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. 41, 1633\u20131644 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1040_CR54","doi-asserted-by":"publisher","first-page":"e65088","DOI":"10.7554\/eLife.65088","volume":"10","author":"F Beghini","year":"2021","unstructured":"Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife 10, e65088 (2021).","journal-title":"eLife"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01040-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01040-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01040-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:07:38Z","timestamp":1751375258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01040-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1040"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01040-w","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}